Prevention of VEGF-mediated microvascular permeability by C-peptide in diabetic mice

Cardiovascular Research

Volumn 101, Issue 1, 2014, Pages 155-164

  Lim, Young Cheol ^a   Bhatt, Mahendra Prasad ^a   Kwon, Mi Hye ^a   Park, Donghyun ^a   Lee, Seungkoo ^a   Choe, Jongseon ^a   Hwang, Jongyun ^a   Kim, Young Myeong ^a   Ha, Kwon Soo ^a  

^a Kangwon National University College of Medicine   (South Korea)

Author keywords

C peptide; Diabetes mellitus; Microvascular permeability; Retinopathy; VEGF

Indexed keywords

C PEPTIDE; DEXTRAN; FLUORESCEIN ISOTHIOCYANATE; REACTIVE OXYGEN METABOLITE; STREPTOZOCIN; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; BLOOD VESSEL PERMEABILITY; CALCIUM CELL LEVEL; CELL JUNCTION; CELL MEMBRANE PERMEABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; EXTRAVASATION; FIBER; HEART LEFT VENTRICLE; HUMAN; HUMAN CELL; MALE; MICROVASCULAR PERMEABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA; SKIN; STRESS; UMBILICAL VEIN ENDOTHELIAL CELL;

C-PEPTIDE; DIABETES MELLITUS; MICROVASCULAR PERMEABILITY; RETINOPATHY; VEGF;

ADHERENS JUNCTIONS; ANIMALS; C-PEPTIDE; CADHERINS; CALCIUM; CAPILLARY PERMEABILITY; CELLS, CULTURED; DIABETIC ANGIOPATHIES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; REACTIVE OXYGEN SPECIES; RETINA; STRESS FIBERS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84891368048     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt238     Document Type: Article

References (46)

1. Wahren J, Kallas A, Sima AA. The clinical potential of C-peptide replacement in type 1 diabetes. Diabetes 2012;61:761-772.
2. Wahren J, Ekberg K, Jornvall H. C-peptide is a bioactive peptide. Diabetologia 2007;50: 503-509.
3. Massi-Benedetti M, Orsini-Federici M. Treatment of type 2 diabetes with combined therapy: what are the pros and cons? Diabetes Care 2008;31(Suppl. 2):S131-S135.
4. Hills CE, Brunskill NJ, Squires PE. C-peptide as a therapeutic tool in diabetic nephropathy. Am J Nephrol 2010;31:389-397.
5. Ido Y, Vindigni A, Chang K, Stramm L, Chance R, Heath WFet al. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 1997;277:563-566.
6. Hills CE, Brunskill NJ. Cellular and physiological effects of C-peptide. Clin Sci (Lond) 2009; 116:565-574.
7. Mughal RS, Scragg JL, Lister P,Warburton P, Riches K, O'Regan DJ et al. Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein. Diabetologia 2010;53:1761-1771.
8. Kobayashi Y, Naruse K, Hamada Y, Nakashima E, Kato K, Akiyama N et al. Human proinsulin C-peptide prevents proliferation of rat aortic smooth muscle cells cultured in high-glucose conditions. Diabetologia 2005;48:2396-2401.
9. Marx N,Walcher D. C-Peptide and atherogenesis: C-peptide as a mediator of lesion development in patients with type 2 diabetes mellitus? Exp Diabetes Res 2008;2008:385108.
10. Johansson BL, Sundell J, Ekberg K, Jonsson C, Seppanen M, Raitakari O et al. C-peptide improves adenosine-induced myocardial vasodilation in type 1 diabetes patients. Am J Physiol Endocrinol Metab 2004;286:E14-E19.
11. Johansson BL, Linde B,Wahren J. Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients. Diabetologia 1992;35:1151-1158.
12. ForstT, HachT, Kunt T,Weber MM,Pfutzner A. Molecular effects of C-peptide in microvascular blood flow regulation. Rev Diabet Stud 2009;6:159-167.
13. Kitamura T, Kimura K, Makondo K, Furuya DT, Suzuki M, Yoshida T et al. Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of wistar rats. Diabetologia 2003;46:1698-1705.
14. Luppi P, Cifarelli V, Tse H, Piganelli J, Trucco M. Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway. Diabetologia 2008;51:1534-1543.
15. Cifarelli V, Geng X, Styche A, Lakomy R, Trucco M, Luppi P. C-peptide reduces high-glucose-induced apoptosis of endothelial cells and decreases NAD(P)H-oxidase reactive oxygen species generation in human aortic endothelial cells. Diabetologia 2011; 54:2702-2712.
16. Bhatt MP, Lim YC, Hwang J, Na S, Kim YM, Ha KS. C-peptide prevents hyperglycemia-induced endothelial apoptosis through inhibition of reactive oxygen species-mediated transglutaminase 2 activation. Diabetes 2013;62:243-253.
17. Bhatt MP, Lim YC, Kim YM, Ha KS. C-peptide activates AMPKa and prevents ROSmediated mitochondrial fission and endothelial apoptosis in diabetes mellitus. Diabetes 2013;62:3851-3862.
18. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD et al. Retinopathy in diabetes. Diabetes Care 2004;27(Suppl. 1):S84-S87.
19. Hoeben A, Landuyt B, Highley MS, Wildiers H,Van OosteromAT,De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56:549-580.
20. Scheppke L, Aguilar E, Gariano RF, Jacobson R, Hood J, Doukas J et al. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest 2008;118:2337-2346.
21. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003;19:442-455.
22. Al-Shabrawey M, Rojas M, Sanders T, Behzadian A, El-Remessy A, BartoliMet al. Role of NADPH oxidase in retinal vascular inflammation. Invest Ophthalmol Vis Sci 2008;49: 3239-3244.
23. Li J,Wang JJ,Yu Q, Chen K, Mahadev K, Zhang SX. Inhibitionof reactive oxygen species by lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4. Diabetes 2010;59:1528-1538.
24. Abid MR, KachraZ, Spokes KC, AirdWC.NADPHOxidase activity is required for endothelial cell proliferation and migration. FEBS Lett 2000;486:252-256.
25. Monaghan-Benson E, Burridge K. The regulation of vascular endothelial growth factorinduced microvascular permeability requires Rac and reactiveoxygen species. J Biol Chem 2009;284:25602-25611.
26. Spindler V, Schlegel N,Waschke J. Role of GTPases in control of microvascular permeability. Cardiovasc Res 2010;87:243-253.
27. May C, Doody JF, Abdullah R, Balderes P, Xu X, Chen CP et al. Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature. Blood 2005;105:4337-4344.
28. Crosby CV, Fleming PA, Argraves WS, Corada M, Zanetta L, Dejana E et al. VE-cadherin is not required for the formation of nascent blood vessels but acts to prevent their disassembly. Blood 2005;105:2771-2776.
29. Kooistra MR, Corada M, Dejana E, Bos JL. Epac1 regulates integrity of endothelial cell junctions through VE-cadherin. FEBS Lett 2005;579:4966-4972.
30. Park JY, Jung SH, JungJW,Kwon MH,YooJO, KimYMet al.Anovel array-based assay of in situ tissue transglutaminase activity in human umbilical vein endothelial cells. Anal Biochem 2009;394:217-222.
31. Yoo JO, Lim YC, Kim YM,Ha KS. Differential cytotoxic responses to low-and high-dose photodynamic therapy in human gastric and bladder cancer cells. J Cell Biochem 2011; 112:3061-3071.
32. Fainaru O, Adini I, Benny O, Bazinet L, Pravda E, D'Amato R et al. Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. FASEB J 2008;22:3728-3735.
33. Kidoya H, Naito H, Takakura N. Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia. Blood 2010;115:3166-3174.
34. Kowluru RA, Tang J, Kern TS.Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. effect of long-termadministration of antioxidants on the development of retinopathy. Diabetes 2001;50:1938-1942.
35. Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:283-290.
36. Maniatis NA, Kotanidou A, Catravas JD, Orfanos SE. Endothelial pathomechanisms in acute lung injury. Vascul Pharmacol 2008;49:119-133.
37. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011;437:169-183.
38. Tiruppathi C,AhmmedGU, Vogel SM, Malik AB.Ca2+signaling,TRP channels, and endothelial permeability. Microcirculation 2006;13:693-708.
39. Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008;266:37-52.
40. Yang B,CaoDJ, Sainz I, ColmanRW,GuoYL. Different roles ofERK and p38MAPkinases during tube formation from endothelial cells cultured in 3-dimensional collagen matrices. J Cell Physiol 2004;200:360-369.
41. Packer MA, Murphy MP. Peroxynitrite formed by simultaneous nitric oxide and superoxide generation causes cyclosporin-A-sensitive mitochondrial calcium efflux and depolarisation. Eur J Biochem 1995;234:231-239.
42. El-Remessy AB, Al-Shabrawey M, Platt DH, Bartoli M, Behzadian MA, GhalyNet al. Peroxynitrite mediates VEGF's angiogenic signal and function via a nitration-independent mechanism in endothelial cells. FASEB J 2007;21:2528-2539.
43. Fukuhara S, Sako K, Noda K, Zhang J, Minami M,Mochizuki N. Angiopoietin-1/Tie2 receptor signaling in vascular quiescence and angiogenesis. Histol Histopathol 2010;25:387-396.
44. Thurston G, Rudge JS, Ioffe E, ZhouH, Ross L, CrollSD et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460-463.
45. Harfouche R, Malak NA, Brandes RP, Karsan A, Irani K, Hussain SN. Roles of reactive oxygen species in angiopoietin-1/tie-2 receptor signaling. FASEB J 2005;19:1728-1730.
46. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007; 2007:1-12.